These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29323755)

  • 1. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
    Nookala AU; Crismale J; Schiano T; Te H; Ahn J; Robertazzi S; Rodigas C; Satoskar R; Kc M; Hassan M; Smith C
    Clin Transplant; 2018 Mar; 32(3):e13198. PubMed ID: 29323755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.
    Dharancy S; Coilly A; Fougerou-Leurent C; Duvoux C; Kamar N; Leroy V; Tran A; Houssel-Debry P; Canva V; Moreno C; Conti F; Dumortier J; Di Martino V; Radenne S; De Ledinghen V; D'Alteroche L; Silvain C; Besch C; Perré P; Botta-Fridlund D; Francoz C; Habersetzer F; Montialoux H; Abergel A; Debette-Gratien M; Rohel A; Rossignol E; Samuel D; Duclos-Vallée JC; Pageaux GP;
    Am J Transplant; 2017 Nov; 17(11):2869-2878. PubMed ID: 28898563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c naïve recipients: A large single center experience.
    Elbeshbeshy H; Modi N; Patel T; Matthews I; Kampert T; Lee J; Okeke R; Caliskan Y; Fleetwood V; Varma C; Gabris B; Bastani B; Abu Al Rub F; Guenette A; Befeler A; Agbim U; Desai R; Alsabbagh E; Qureshi K; Schnitzler M; Lentine KL; Randall HB; Nazzal M
    Clin Transplant; 2024 Jan; 38(1):e15161. PubMed ID: 37842872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.
    Zhang J; Sun W; Lin J; Tian Y; Ma L; Zhang L; Zhu Y; Qiu W
    BMC Infect Dis; 2019 Jul; 19(1):645. PubMed ID: 31324230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
    PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
    Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
    Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
    Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.